Document:

Second Amended and Restated License Agreement

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Exhibit 10.5 

2020.LICI.001.B                

California Institute of Technology 
 SECOND AMENDED AND RESTATED LICENSE AGREEMENT 
 THIS SECOND AMENDED AND
RESTATED LICENSE AGREEMENT (“Agreement”), effective May 1, 2000 (the “Effective Date”) with a second restatement date as of May 1, 2004 (the “Second Restatement Date”), between CALIFORNIA INSTITUTE OF
TECHNOLOGY , 1200 East California Boulevard, Pasadena, California 91125 (“Caltech”) and FLUIDIGM CORPORATION , 7100 Shoreline Court, South San Francisco, California 94080 (formerly Mycometrix Corporation) (“Licensee”).

 WHEREAS, Caltech has been engaged in basic research in the field of microfluidics; 

WHEREAS, that research led to the United States patents, patent applications and other inventions listed in Exhibit A, which
are owned, solely or jointly, by Caltech; 
 WHEREAS, Licensee is desirous of obtaining, and Caltech wishes to grant to
Licensee, an exclusive license (or the maximum rights Caltech can grant) to the Licensed Patents (as defined in Section 1.5) and Improvements thereof in the Field (as defined in Sections 1.4 and 1.3, respectively) and an exclusive license
to the Technology (as defined in Section 1.9); 
 WHEREAS, the Caltech and Licensee have entered into a prior
License Agreement made as of May 1, 2000, and an Amended and Restated License Agreement made as of June 1, 2002, which the parties now wish to further amend and restate as set forth herein. 

NOW, THEREFORE, the parties agree as follows: 

  
 - 1 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 ARTICLE 1 
 DEFINITIONS 
 1.1 “Affiliate” shall mean, with respect to
Licensee, any entity which controls, is controlled by or is under common control with Licensee. An entity shall be regarded as in control of another entity for purposes of this definition if it owns or controls fifty percent (50%) or more of
the shares of the subject entity entitled to vote in the election of directors (or, in the case of an entity that is not a corporation, for the election of the corresponding managing authority). “Affiliate” shall mean, with respect to
Caltech, any research entity which is operated or managed as a facility under Caltech. 
 1.2 “Deductible
Expenses” means (i) all trade, cash and quantity credits, discounts, refunds or government rebates; (ii) amounts for claims, allowances or credits for returns, retroactive price reductions, or chargebacks; (iii) packaging,
handling fees and prepaid freight, sales taxes, duties and other governmental charges (including value added tax); and (iv) provisions for uncollectible accounts determined in accordance with reasonable accounting practices, consistently
applied to all products of the selling party. For the removal of doubt, Net Sales shall not include sales by Licensee to its Affiliates for resale, provided that if Licensee sells a Licensed Product to an Affiliate for resale, Net Sales shall
include the amounts invoiced by such Affiliate to third parties on the resale of such Licensed Product. In the event that Licensee grants a sublicense hereunder, and receives payments based upon the Sublicensee’s sales of Licensed Products,
Licensee may upon notice to Caltech modify this definition of “Net Sales” for purposes of calculating royalties payable to Caltech on such Sublicensee’s sales to be the same as the definition of “Net Sales” on which such
royalties to Licensee are calculated. 
 1.3 “Field” means [***] 

  
 - 2 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 [***] 
 1.4 “Improvements” shall mean all Caltech rights (whether or not Caltech has sole or joint rights) in any improvement or invention conceived and reduced to practice or otherwise developed
in or arising from research in the Field as conducted by Dr. Stephen Quake, researchers of the Quake laboratory, or in collaboration with members of the Frances Arnold or Axel Scherer laboratories, whether invented solely by Caltech researchers
or jointly with (i) Licensee or (ii) other researchers without an obligation of assignment to Caltech. 
 1.5
“Licensed Patents” means the patent applications listed in Exhibit A hereto; any patents issuing on such patent applications, all divisionals, continuations, continuations-in-part, patents of addition, substitutions,
registrations, reissues, reexaminations or extensions of any kind with respect to any of the existing patents and any foreign counterparts of such patent applications and patents, and Improvements. 

1.6 “Licensed Product” means products covered by a Valid Claim of a Licensed Patent in the country in which such product
is sold or products in which the Technology is utilized. 
 1.7 “Net Sales” means the total amount invoiced to
third parties on sales of Licensed Products for which royalties are due under Article 4 below, less, to the extent allocable to such invoiced amounts, Deductible Expenses. 

1.8 “Sublicensee” shall mean any non-Affiliate third party to whom Licensee has granted the right under the Licensed
Patents and Technology to manufacture and sell Licensed Products, with respect to Licensed Products made and sold by such third party. 

  
 - 3 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 1.9 “Technology” means all proprietary information, know-how,
procedures, methods, prototypes, designs, technical data, reports, and data owned by Caltech that are necessary or useful in the development of products in the Field covered by any issued patent or pending patent application within the Licensed
Patents, and which relate to such products. 
 1.10 “Valid Claim” means a claim of an issued and unexpired
patent or a claim of a pending patent application within the Licensed Patents which has not been held unpatentable, invalid or unenforceable by a court or other government agency of competent jurisdiction and has not been admitted to be invalid or
unenforceable through reissue, re-examination, disclaimer or otherwise; provided, however, that if the holding of such court or agency is later reversed by a court or agency with overriding authority, the claim shall be reinstated as a Valid Claim
with respect to Net Sales made after the date of such reversal. Notwithstanding the foregoing provisions of this Section 1.10, if a claim of a pending patent application within the Licensed Patents has not issued as a claim of an issued patent
within the Licensed Patents, within five (5) years after the filing date from which such claim takes priority, such pending claim shall not be a Valid Claim for purposes of this Agreement. 

ARTICLE 2 

PATENT LICENSE GRANT 
 2.1 Caltech hereby grants to Licensee an exclusive, royalty-bearing, worldwide license, with the right to grant and authorize sublicenses, under the Licensed Patents and Technology to make, have made,
use, import, offer for sale and sell Licensed Products, practice any method or procedure and otherwise exploit the Licensed Patents and Technology. 
 2.2 These licenses are subject to: (a) the reservation of Caltech’s right to make, have made, and use Licensed Products for noncommercial educational and research purposes, but not for sale or
other distribution to third parties; and (b) the rights of the U.S. Government under Title 35, United States Code, Section 200 et seq., including but not limited to the grant to the U.S. government of a nonexclusive, nontransferrable,
irrevocable, paid-up license to practice or have practiced any invention conceived or first actually reduced to practice in the performance of work for or on behalf of the U.S. Government throughout the world. These licenses are not

  
 - 4 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
transferable by Licensee except as provided in Section 16.4, but Licensee shall have the right to grant non-exclusive or exclusive sublicenses hereunder, provided that: 

(a) License shall include all its sublicensing income in Licensee’s reports to Caltech, as provided in Section 9.2, and
Licensee shall pay royalties thereon to Caltech pursuant to Section 4.2 and 4.4; 
 (b) Licensee shall furnish Caltech
within thirty (30) days of the execution thereof, a true and complete copy of each sublicense and any changes or additions thereto; 
 (c) License may grant sublicenses of no greater scope than the license granted under Section 2.1; and 
 Each sublicense granted by Licensee shall include provisions similar in all material respects to those of Articles 6, 12, 15, 16 and Section 2.2. 

ARTICLE 3 

IMPROVEMENTS 
 3.1 The parties acknowledge that Exhibit A includes all Improvements disclosed by Caltech to Licensee between May 1, 2000 and the Second Restatement Date, and elected by Licensee as of the
Second Restatement Date. Caltech shall notify Licensee in writing of Improvements made after the Second Restatement Date and during the term of the Agreement. Upon receipt of an invention disclosure constituting an Improvement, Licensee can elect to
add such Improvement and any related patent filings to Exhibit A hereof to be within the Licensed Patents. Thereafter, Licensee shall be responsible for patent prosecution and costs associated with such elected Improvement in accordance with
Article 11 herein, as well as to issue additional stock pursuant to Section 5.3. No less than at each anniversary of the Second Restatement Date, Exhibit A shall be updated by the parties to reflect the inclusion of all Improvements
so elected, as well as updates on all Licensed Patents. 

  
 - 5 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 ARTICLE 4 
 ROYALTIES 
 4.1 With respect to Licensed Products manufactured or sold by
Licensee in a country in which such manufacture or sale is covered by a Valid Claim of a Licensed Patent, Licensee agrees to pay Caltech [***] of Net Sales of such Licensed Products wherein the Licensed Products are instruments or apparatus directly
used for the reading and/or analysis of data from other Licensed Products, including microfluidic chips that are Licensed Products, and [***] of Net Sales of Licensed Products by Licensee for all such other Licensed Products, including microfluidic
chips that are Licensed Products, Royalties due under this Section 4.1 shall be payable on a country-by-country and Licensed Product-by-Licensed Product basis until the expiration of the last-to-expire issued Valid Claim covering such Licensed
Product in such country. 
 4.2 With respect to Licensed Products manufactured or sold by Sublicensees in a country in which
such manufacture or sale is covered by a Valid Claim of a Licensed Patent, Licensee agrees to pay Caltech [***] of the revenues received by Licensee from Sublicensees’ Net Sales of such Licensed Products wherein the Licensed Products are
instruments or apparatus directly used for the reading and/or analysis of data from other Licensed Products, including microfluidic chips that are Licensed Products, and [***] of the revenues received by Licensee from Sublicensees’ Net Sales of
Licensed Products for all such other Licensed Products, including microfluidic chips that are Licensed Products. Royalties due under this Section 4.2 shall be payable on a country-by-country and Licensed Product-by-Licensed Product basis until
the expiration of the last-to-expire issued Valid Claim covering such Licensed Product in such country. 
 4.3 With respect to
Licensed Products manufactured or sold by Licensee in a country in which such manufacture or sale is not covered by Valid Claim of a Licensed Patent but the Technology is utilized, Licensee agrees to pay Caltech [***] of Net Sales of such Licensed
Products by Licensee, wherein the Licensed Products are instruments or 

  
 - 6 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
apparatus directly used for the reading and/or analysis of data from other Licensed Products, including microfluidic chips that are Licensed Products, and [***] of Net Sales of Licensed Products
by Licensee for all such other Licensed Products, including microfluidic chips that are Licensed Products. Royalties due under this Section 4.3 shall be payable on a country-by-country and Licensed Product-by-Licensed Product basis for a period
of [***] years from the Effective Date or the issuance of a U.S. patent that covers the Licensed Product, whichever first occurs. 
 4.4 With respect to Licensed Products manufactured or sold by Sublicensees in a country in which such manufacture or sale is not covered by a Valid Claim of a Licensed Patent but the Technology is
utilized, Licensee agrees to pay Caltech [***] of the revenues received by Licensee from Sublicensees’ Net Sales of such Licensed Products wherein the Licensed Products are instruments or apparatus directly used for the reading and/or analysis
of data from other Licensed Products, including microfluidic chips that are Licensed Products, and [***] of the revenues received by Licensee from Sublicensees’ Net Sales of Licensed Products for all such other Licensed Products, including
microfluidic chips that are Licensed Products. Royalties due under this Section 4.4 shall be payable on a country-by-country and Licensed Product-by-Licensed Product basis for a period of [***] years from the Effective Date or the issuance of a
U.S. patent that covers the Licensed Product, whichever first occurs. 
 4.5 Notwithstanding the above, it is understood and
agreed that Caltech shall not be entitled to any share of amounts received by Licensee for equity, debt, pilot studies, to support research or development activities to be undertaken by Licensee, research and development or other performance based
milestones, the achievement by Licensee or Sublicensee of specified milestones or benchmarks relating to the development of Licensed Products, the license or sublicense of any intellectual property other than the Licensed Patents, reimbursement for
patent or other expenses, or with respect to products other than Licensed Products. 
 4.6 In the event that a Licensed Product
is sold in combination with one or more other products or other items that are not Licensed Products, Net Sales for such combination products will be reasonably calculated on a country-by-country and Licensed Product-by-Licensed

  
 - 7 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
Product basis by Licensee by multiplying the Net Sales of that combination by a fraction equal to the relative value of the combination attributable to the Licensed Product, in relation to the
relative value of the combination, as reasonably determined by Licensee in good faith. In addition, in the event that a Licensed Product is not sold in combination with one or more other products or other items that are not Licensed Products, but
instead comprises multiple components, some of which would constitute a Licensed Product if sold separately (each, a “Licensed Component”), and the others would not constitute a Licensed Product if sold separately, then Net Sales for such
Licensed Product will be calculated by multiplying the Net Sales of such Licensed Product by the fraction A/B, where A is the gross selling price of the Licensed Component sold separately and B is the gross selling price of such Licensed Product. If
no such separate sales are made by Licensee, its Affiliate or Sublicensee, Net Sales for such Licensed Product shall be calculated by multiplying Net Sales of such Licensed Product by the fraction C/(C+D), where C is the fully allocated cost of the
Licensed Component and D is the fully allocated cost of the other components. 
 4.7 Commencing on January 1, 2004, and
continuing for each anniversary thereof during the term of this Agreement, if Licensee has not paid, during the preceding calendar year, a minimum of [***] in royalties under Sections 4.1, 4.2, 4.3, and 4.4, Licensee agrees to pay, on or before
March 1 of that calendar year, an additional royalty for the prior calendar year equal to the difference between [***] and any lower amount paid under Sections 4.1, 4.2, 4.3, and 4.4 for the prior calendar year. 

4.8 In the event Licensee or Sublicensee becomes obligated to pay amounts to a third party with respect to a Licensed Product for patent
rights of a third party, Licensee may deduct [***] of the amounts owing to such third party (prior to reductions) from the amount owing to Caltech for such Licensed Product; provided, however, the amounts otherwise due to Caltech shall not be so
reduced by more than [***]. 
 4.9 For the purpose of determining royalties payable under this Agreement, any royalties or other
revenues Licensee receives from Sublicensees in currencies other than U.S. dollars and any Net Sales denominated in currencies other than U.S. dollars shall be converted 

  
 - 8 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
into U.S. dollars according to Licensee’s reasonable standard internal conversion procedures, including Licensee’s standard internal rates and conversion schedule. 

4.10 No more than one royalty payment shall be due with respect to a sale of a particular Licensed Product. No multiple royalties shall
be payable because any Licensed Product, or its manufacture, sale or use is covered by more than one Valid Claim in a given country. No royalty shall be payable under this Article 4 with respect to Licensed Products distributed for use in
research and/or development or as promotional samples or otherwise distributed without charge to third parties. 
 4.11 Any
sublicenses granted by Licensee, including, without limitation, any nonexclusive sublicenses, shall remain in effect in the event this license terminates pursuant to Article 12; provided, the financial obligations of each Sublicensee to Caltech
shall be limited to the amounts Licensee shall be obligated to pay Caltech for the activities of such Sublicensee pursuant to this Agreement. 
 4.12 Royalties due under this Article 4 shall be payable on a country-by-country and Licensed Product-by-Licensed Product basis until the expiration of the last-to-expire issued Valid Claim covering
such Licensed Product in such country, if the manufacture or sale of such Licensed Product was at the time of the first commercial sale in such country covered by a Valid Claim. Otherwise, royalties due under this Article 4 shall be payable on
a country-by-country and Licensed Product-by-Licensed Product basis until [***] whichever first occurs. 
 4.13 Notwithstanding
the provisions of this Article 4, no royalty shall be payable to Caltech with respect to any sales of Licensed Products to the U.S. Government on sales made solely to permit the U.S. Government to practice or have practiced or have practiced or
sue on its behalf any invention or process covered by the Licensed Patents. 
 ARTICLE 5 

LICENSEE EQUITY INTEREST 
 5.1 In accordance with the License Agreement of May 1, 2000, Licensee issued to Caltech, in consideration of Licensee’s receipt of the intangible property rights granted under

  
 - 9 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
that License Agreement (which rights are carried forward herein), [***] shares of common stock of Licensee, pursuant to the terms of a reasonable and customary stock issuance agreement. Further,
it is acknowledged that, as partial consideration for entering into the first Amended and Restated License Agreement of June 1, 2002, with the reformation of the initial License Agreement of May 1, 2000 and the associated restatements and
amendments (including, but not limited to, an updated Exhibit A), Licensee issued to Caltech [***] shares of common stock of Licensee. 
 5.2 Caltech agrees that, in the event of any underwritten or public offering of securities of Licensee or a Affiliate, Caltech shall comply with and agree to any reasonable restriction on the transfer of
equity interest, or any part thereof, imposed by an underwriter, and shall perform all acts and sign all necessary documents required with respect thereto. 
 5.3 If Licensee wishes at its sole discretion to license hereunder any Improvements disclosed by Caltech to Licensee during a twelve (12) month period beginning with June 1, 2003, and for each
anniversary thereafter (each twelve month period will be referred to as an “Improvement Period”), Licensee shall notify Caltech in writing accordingly within thirty (30) days after the end of each Improvement Period. For the first two
(2) Improvement Periods, Licensee agrees to issue to Caltech, in consideration of Licensee’s election to receive additional intangible property rights to all Improvements disclosed to Licensee during an Improvement Period, [***] shares of
common stock of Licensee, pursuant to the terms of a reasonable and customary stock issuance agreement. Thereafter, Licensee is hereby granted an option by Caltech that Licensee can exercise during the final year of the first two
(2) Improvement Period on an annual basis on the same terms and conditions. The consideration of this option was partially paid by the [***] shares granted by Licensee to Caltech as referenced in Section 5.1 of this Agreement. Further, it
is acknowledged that pursuant to the initial License Agreement of May 1, 2000 and the first Amended and Restated License Agreement of June 1, 2002, Licensee elected to receive additional intangible property rights to Improvements disclosed
to Licensee by Caltech during May 1, 2000 through May 31, 2003, in consideration of the issuance to Caltech by Licensee of [***] shares of common stock of Licensee (which represents the [***] share grant under Section 5.1 above and
[***] shares pursuant to the parties’ 

  
 - 10 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
Letter Agreement dated June 19, 2003, paragraph #3), receipt of which shares Caltech hereby acknowledges. 
 ARTICLE 6 
 DUE DILIGENCE 

6.1 Licensee agrees to use commercially reasonable efforts to introduce commercial Licensed Product(s) as soon as practical, consistent
with sound and reasonable business practices and judgments. Licensee shall be deemed to have satisfied its obligations under this Section if Licensee has an ongoing and active research program or marketing program, as appropriate, directed toward
production and use of one or more Licensed Products. Any efforts of Licensee’s Sublicensees shall be considered efforts of Licensee for the sole purpose of determining Licensee’s compliance with its obligation under this Section.

 6.2 After the first year from the Effective Date, Caltech shall have the right, no more often than once each year, to require
Licensee to report to Caltech in writing on its progress in introducing commercial Licensed Product(s) in the United States. 

6.3 If Licensee is not fulfilling its obligations under Section 6.1 with respect to the Field and Caltech so notifies Licensee in
writing, Caltech and Licensee shall negotiate in good faith any additional efforts to be taken by Licensee. If the parties do not reach agreement within ninety (90) days, the parties shall submit the issue to arbitration as provided in
Article 14 to determine whether any additional efforts shall be required of Licensee. If subsequent to the conclusion of such arbitration proceedings Licensee then fails to make any required efforts, and does not remedy that failure within
sixty (60) days after further written notice to Licensee, Caltech may convert the license granted in Section 2.1 to a nonexclusive license in any part of the Field in which Licensee is not fulfilling its obligations under Section 6.1,
and the royalties payable under this Agreement shall be reduced by [***] for Licensed Products in the Field sold under such a nonexclusive license. 

  
 - 11 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 ARTICLE 7 
 INFRINGEMENT BY THIRD PARTY 
 7.1 Both Caltech and Licensee agree to notify
the other in writing should either party become aware of infringement of the Licensed Patents. Licensee, upon notice to Caltech, shall have the sole right to initiate an action against the infringer at Licensee’s expense, either in
Licensee’s name or in Caltech’s name if so required by law, Licensee shall have sole control of the action. 
 7.2 If
Licensee, its Affiliate or Sublicensee, distributor or other customer is sued by a third party charging infringement of patent rights that dominate a claim of the Licensed Patents or that cover the development, manufacture, use, distribution or sale
of a Licensed Product, Licensee will promptly notify Caltech. As between the parties to this Agreement, Licensee shall have sole control of the defense in any such action(s). 
 7.3 If a declaratory judgment action alleging invalidity unenforceability or noninfringement of any of the Licensed Patents is brought against Licensee and/or Caltech, Licensee may elect to have sole
control of the action, and if Licensee so elects it shall bear all the costs of the action. Licensee also may elect to undertake and have sole control of the defense of any interference, opposition or similar action with respect to the Licensed
Patents providing it bears all the costs of such action. 
 7.4 In the event Licensee institutes a legal action pursuant to
Section 7.1, within thirty (30) days after receipt of notice of Licensee’s intent to institute such legal action, Caltech shall have the right to jointly prosecute such action and to fund up to one-half ( 1/2) the costs of such action. Caltech shall fully cooperate with and
supply all assistance reasonably requested by Licensee, including by using commercially reasonable efforts to have its employees testify when requested and to make available relevant records, papers, information, samples, specimens, and the like.
Licensee shall bear the reasonable expenses incurred by Caltech in providing such assistance and cooperation as is requested pursuant to this Section 7.4. Licensee shall keep Caltech reasonably informed of the progress of the legal action, and
Caltech shall be entitled to be represented by counsel in connection with such legal action at its own expense. Licensee’s 

  
 - 12 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
reasonable and customary expenses for such action (including attorneys’ fees and expert fees) shall be fully creditable against royalties owed to Caltech hereunder, provided that in no one
year shall such expenses to be credited against more than [***] of royalty payments to Caltech. Any remaining expenses may be carried over and credited against royalties owed in future years. 

7.5 Licensee shall have the light to settle any claims, but only upon terms and conditions that are reasonably acceptable to Caltech.
Should Licensee elect to abandon such an action other than pursuant to a settlement with the alleged infringer that is reasonably acceptable to Caltech, Licensee shall give timely notice to Caltech who, if it so desires, may continue the action;
provided, however, that the sharing of expenses and any recovery in such suit shall be as agreed upon between the parties. 

7.6 Any amounts paid to Licensee by third parties as the result of an action pursuant to this Article 7 (such as in satisfaction of
a judgment or pursuant to a settlement) shall first be applied to reimbursement of the unreimbursed expenses (including attorneys’ fees and expert fees) incurred by Licensee and then to the payment to Caltech of any royalties against which were
credited expenses of the action in accordance with Section 7.4. Any remainder shall be divided between the parties as follows: 
 (a) To the extent the amount recovered reflects lost profits, Licensee shall retain the remainder, less the amount of any royalties that would have been due Caltech on sales of Licensed Product lost
by Licensee as a result of the infringement had Licensee made such sales, provided that (i) Licensee shall in any event retain at least [***] of the remainder; and (ii) Caltech shall receive an amount equal to the royalties it would have
received if such sales had been made by Licensee, provided such amount shall in no event exceed [***] of the remainder; or 

(b) To the extent the amount recovered does not reflect lost profits, such amount shall be shared by Caltech and Licensee pro rata
according to the respective percentages of costs borne by each in such action; provided, however, that in no event shall Caltech receive less than twenty-five percent (25%) of such amount. 

  
 - 13 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 ARTICLE 8 
 BENEFITS OF LITIGATION, 
 EXPIRATION OR ABANDONMENT 

8.1 In a case where one or more patents or particular claims thereof within the Licensed Patents expire, or are abandoned, or are
declared invalid or unenforceable or otherwise construed by a court of last resort or by a lower court from whose decree no appeal is taken, or certiorari is not granted within the period allowed therefor, then the effect thereof hereunder shall be:

 (a) that such patents or particular claims shall, as of the date of expiration or abandonment or final decision as the
case may be, cease to be included within the Licensed Patents for the purpose of this Agreement; 
 (b) that such
construction so placed upon the Licensed Patents by the court shall be followed from and after the date of entry of the decision, and royalties shall thereafter be payable by Licensee only in accordance with such construction; and 

(c) In the event that Licensee challenges the validity of Licensed Patents, Licensee may not cease paying royalties as of the date
validity of the claims in issue are challenged, but rather may cease paying royalties as to those claims only after a final adjudication of invalidity of those claims. 
 8.2 In the event that any of the contingencies provided for in Section 8.1 occurs, Caltech agrees to renegotiate in good faith with Licensee a reasonable royalty rate under the remaining Licensed
Patents which are unexpired and in effect and under which Licensee desires to retain a License. 
 ARTICLE 9 

RECORDS, REPORTS AND PAYMENTS 
 9.1 Licensee shall keep records and books of account in respect of all Licensed Products made and sold by Licensee or its Affiliates under this Agreement and of royalties or other revenues Licensee
receives from Sublicensees other than Licensee’s Affiliates for the sale 

  
 - 14 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
of Licensed Products. Caltech shall have the right at its own cost, during Licensee’s business hours, no more often than annually, to have an independent certified public accounting firm of
nationally recognized standing to examine such records and books. Licensee shall keep the same for at least three (3) years after it pays Caltech the royalties due for such Licensed Products and require Licensee’s Affiliates to do the
same. The accounting firm shall disclose to Caltech only whether or not the reports are correct and the amount of any discrepancies. Caltech shall, and shall cause its accounting firm to, not disclose to any third party any confidential information
learned through an examination of such records and books. 
 9.2 Following the first commercial sale of a Licensed Product, on
or before the last day of each February, May, August and November for so long as royalties are payable under this Agreement, Licensee shall render to Caltech a report in writing, setting forth Net Sales and the number of units of Licensed Products
sold during the preceding calendar quarter by Licensee and its Affiliates, and the royalties or other revenues received by Licensee from Net Sales of Licensed Products made by Licensee’s Sublicensees other than Affiliates during the preceding
calendar quarter. Each such report shall also set forth an explanation of the calculation of the royalties payable hereunder and be accompanied by payment of the royalties shown by said report to be due Caltech. Notwithstanding foregoing, if
(i) Caltech materially breaches this Agreement, (ii) Licensee gives Caltech written notice of the breach, and (iii) Caltech has not cured the breach by the time a payment is due under this Section, then Licensee may make the required
payment into an interest bearing escrow account to be released when the breach is cured, less any damages that may be payable to License by virtue or Caltech’s breach. Royalty reports which are not challenged by Caltech or amended by Licensee
within thirty-six (36) months after receipt by Caltech shall be conclusively presumed correct and not subject to challenge, audit, or amendment. 
 ARTICLE 10 
 CONFIDENTIALITY 

10.1 Except as provided herein, each party shall maintain in confidence, and shall not use for any purpose or disclose to any third
party, information disclosed by the other party in writing and marked “Confidential” or that is disclosed orally and confirmed in writing as 

  
 - 15 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
confidential within forty-five (45) days following such disclosure (collectively, “Confidential Information”). Confidential Information shall not include any information that is;
(i) already known to the receiving party at the time of disclosure hereunder, (ii) now or hereafter becomes publicly known other than through acts or omissions of the receiving party, (iii) disclosed to the receiving party by a third
party under no obligation of confidentiality to the disclosing party, (iv) disclosed as required by securities or other applicable laws or pursuant to legal requirement, or (v) disclosed to actual or prospective investors or corporate
partners, or to a party’s accountants, attorneys, and other professional advisors. All reports provided to Caltech by Licensee pursuant to this Agreement shall be treated as confidential information of Licensee, pursuant to this
Section 10.1. The terms of this Agreement shall be treated as confidential information of Licensee, pursuant to this Section 10.1. 
 10.2 Notwithstanding the provisions of Section 10.1 above, Licensee may use or disclose confidential information comprising the Licensed Patents and Technology to the extent necessary to exercise its
rights hereunder (including commercialization and/or sublicensing of the Licensed Patents and Technology) or fulfill its obligations and/or duties hereunder and in filing for, prosecuting or maintaining any proprietary rights, prosecuting or
defending litigation, complying with applicable governmental regulations and/or submitting information to tax or other governmental authorities. 
 ARTICLE 11 
 PATENT PROSECUTION AND PATENT COSTS 

11.1 Licensee shall have the right to apply for, prosecute and maintain during the term of this Agreement, the Licensed Patents. Caltech
shall provide Licensee with timely disclosures regarding Improvements and potential Improvements. The application filings, prosecution, maintenance and payment of all fees and expenses, including legal fees, relating to such Licensed Patents shall
be the responsibility of Licensee, provided that Licensee shall pay for all reasonable fees and expenses, including reasonable legal fees, incurred in such application filings, prosecution and maintenance. Caltech shall provide Licensee with all
information necessary or useful for the filing and prosecution of such Licensed Patents and shall cooperate fully with Licensee so that Licensee may establish and maintain such rights. Patent attorneys

  
 - 16 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
chosen by Licensee shall handle all patent filings and prosecutions, on behalf of Caltech, provided, however, Caltech shall be entitled to review and comment upon and approve all actions
undertaken in the prosecution of all patents and applications. Caltech shall provide any comments or approvals hereunder promptly. 
 11.2 In the event Licensee declines to apply for, prosecute or maintain any Licensed Patents, Caltech shall have the right to pursue the same at Caltech’s expense and Licensee shall have no rights
under Caltech’s interest therein. If Licensee decides not to apply for, prosecute or maintain any Licensed Patents, Licensee shall give sufficient and timely notice to Caltech so as to permit Caltech to apply for, prosecute and maintain such
Licensed Patents. In such event, Licensee shall provide Caltech with all information necessary or useful for the filing and prosecution of such Licensed Patents and shall cooperate fully with Caltech so that Caltech may establish and maintain such
rights. 
 11.3 Licensee shall reimburse Caltech for all reasonable out-of-pocket expenses incurred by Caltech for the filing
for, prosecution and maintenance of the Licensed Patents Rights. Such expenses shall be reimbursed following receipt by Licensee from Caltech of (i) an invoice covering such fees (including copies of invoices for legal fees describing the legal
services performed in reasonable detail) and (ii) reasonably satisfactory evidence that such fees were paid. Initially, payments shall be made in six (6) equal quarterly installments due within ten days after the end of the first six
(6) full calendar quarters, effective twenty-four (24) months from the Effective Date of this Agreement. Subsequent payments under this Section 11.3 shall be made to Caltech within sixty (60) days following receipt by Licensee
from Caltech of (i) an invoice covering such fees (including copies of invoices for legal fees describing the legal services performed in reasonable detail) and (ii) reasonably satisfactory evidence that such fees were paid. If Licensee
elects to no longer pay the expenses of a patent or patent application within the Licensed Patents in any country, Licensee shall notify Caltech not less than thirty (30) days prior to such action. In the event that Licensee elects not to pay
such expenses the license granted to Licensee hereunder shall terminate. [***] of patent expenses paid by Licensee in conjunction with foreign patent costs shall be creditable against earned royalties due Caltech in the respective territory covered
by the patent or patents that are foreign filed. 

  
 - 17 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 ARTICLE 12 

TERMINATION 
 12.1 The term of this Agreement shall commence upon the Effective Date and shall terminate on a country-by-country and Licensed Product by Licensed Product basis upon the expiration of the last to expire
Licensed Patent in such country. Caltech shall have the right to terminate this Agreement, subsequent to and subject to the outcome of arbitration proceedings pursuant to Article 14, prior to the date it would otherwise expire pursuant to this
Section 12.1 if Licensee fails to make any payment due hereunder and Licensee continues to fail to make the payment, either to Caltech directly or by placing any disputed amount into an interest bearing escrow account to be released when the
dispute is resolved, for a period of sixty (60) days after receiving written notice from Caltech specifying Licensee’s failure. If this Agreement expires pursuant to the first sentence of this Section 12.1, Licensee shall retain a
nonexclusive, perpetual, royalty-free, worldwide license, with the right to sublicense, under the Licensed Patents and Technology, to research, develop, make, use, sell, offer for sale and import Licensed Products. 

12.2 If either party materially breaches this Agreement, the other party may elect to give the bleaching party written notice describing
the alleged breach. If the breaching party has not cured such breach within sixty (60) days after receipt of such notice, the notifying party will be entitled, in addition to any other rights it may have under this Agreement, to terminate this
Agreement effective immediately; provided, however, that if either party receives notification from the other of a material breach and if the party alleged to be in default notifies the other party in writing within thirty (30) days of receipt
of such default notice that it disputes the asserted default, the matter will be submitted to arbitration as provided in Article 14 of this Agreement. In such event, the nonbreaching party shall not have the right to terminate this Agreement
until it has been determined in such arbitration proceeding that the other party materially breached this Agreement, and the breaching party fails to cure such breach within ninety (90) days after the conclusion of such arbitration proceeding.

 12.3 Licensee shall have the right to terminate this Agreement either in its entirety or as to any jurisdiction or any part
of the Licensed Patents or Technology upon thirty (30) days 

  
 - 18 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
written notice. If Licensee does so, it shall submit all required reports and make all required payments in accordance with Section 9.2 

12.4 In the event of any termination or expiration of the term of this Agreement, Licensee shall have the right to use or sell Licensed
Products on hand on the date of such termination or expiration and to complete Licensed Products in the process of manufacture at the time of such termination or expiration and use or sell the same, provided that Licensee shall submit the applicable
royalty report described in Section 9.2, along with the royalty payments required above in accordance with Section 4.1 for sale of such Licensed Products, provided that the Licensed Products are still covered by a Valid Claim following
such termination or expiration. 
 12.5 Termination of this Agreement for any reason shall not release any party hereto from any
liability which, at the time of such termination, has already accrued to the other party or which is attributable to a period prior to such termination, nor preclude either party from pursuing any rights and remedies it may have hereunder or at law
or in equity which accrued or are based upon any event occurring prior to such termination. 
 12.6 Section 5.2 and
Articles 10, 12, 14, and 16 of this Agreement shall survive termination of this Agreement for any reason. 
 12.7 If Licensee is
acquired by or merges into a third party (i.e., Licensee is not a surviving company in the merger), then Caltech may terminate its obligations to disclose and grant licenses to Improvements by providing notice to Licensee of that termination. The
remainder of the Agreement and the licenses granted hereunder (including prior licenses granted to Improvements) continues. 

ARTICLE 13 

WARRANTIES AND NEGATION OF 
 WARRANTIES, IMPLIED LICENSES AND AGENCY 
 13.1 Caltech represents and
warrants that (i) it owns all right, title and interest in and to the Licensed Patents and Technology, (ii) it has the right to enter into this Agreement, (iii) it has not granted and will not grant during the term of this Agreement
rights in or to any Licensed 

  
 - 19 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
Patents or Technology that are inconsistent with the rights granted to Licensee herein, (iv) to Caltech’s knowledge, there are no claims of third parties that would call into question
the rights of Caltech to grant to Licensee the rights contemplated hereunder; (v) to Caltech’s knowledge, practice of the Licensed Patents will not infringe intellectual property rights of third parties; (vi) except for the Licensed
Patents, as of the effective date of the Agreement, to Caltech’s belief and knowledge, Caltech does not own or control any patents or patent applications that would dominate any practice of the Licensed Patents or Technology, and
(vii) there are no threatened or pending actions, suits, investigations, claims, or proceedings in any way relating to the Licensed Patents or Technology. 
 13.2 Nothing in this Agreement shall be construed as: 
 (a) a representation
or warranty of Caltech as to the validity or scope of Licensed Patents or any claim thereof; or 
 (b) an obligation to
bring or prosecute actions or suits against third parties for infringement. 
 (c) conferring by implication, estoppel or
otherwise, any license or rights under any existing patents of Caltech other than Licensed Patents, regardless of whether such other patents are dominant or subordinate to Licensed Patents. Notwithstanding the foregoing, and to the extent legally
permissible, Caltech hereby grants Licensee a right of first refusal as to such dominant or subordinate patents, providing that a Caltech faculty member does not wish to personally commercialize the technology embodied in such patents. 

13.3 CALTECH MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND ASSUMES NO
RESPONSIBILITIES WHATEVER WITH RESPECT TO THE USE, SALE, OR OTHER DISPOSITION BY LICENSEE OF LICENSED PRODUCT(S). 
 13.4
Caltech shall indemnify, defend and hold harmless Licensee from and against any and all losses, damages, costs and expenses (including attorneys’ fees) arising out of a material breach by Caltech of its representations and warranties
(“Claims”), provided that (i) Caltech is notified promptly of any Claims, (ii) Licensee has the sole right to control and defend or settle 

  
 - 20 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
any litigation within the scope of this indemnity, and (iii) all indemnified parties cooperate to the extent necessary in the defense of any Claims. 

ARTICLE 14 

ARBITRATION 
 14.1 Any dispute under this Agreement which is not settled by mutual consent shall be finally settled by binding arbitration, conducted in accordance with the Commercial Arbitration Rules of the American
Arbitration Association by one (1) independent, neutral arbitrator appointed in accordance with said rules. The arbitration shall be held in San Francisco, California. The arbitrators shall determine what discovery shall be permitted,
consistent with the goal of limiting the cost and time that the parties must expend for discovery; provided the arbitrators shall permit such discovery as they deem necessary to permit an equitable resolution of the dispute. Any written evidence
originally in a language other than English shall be submitted in English translation accompanied by the original or a true copy thereof. Except as otherwise expressly provided in this Agreement, the costs of the arbitration, including
administrative and arbitrator(s)’ fees, shall be shared equally by the parties and each party shall bear its own costs and attorneys’ and witness’ fees incurred in connection with the arbitration. A disputed performance or suspended
performances pending the resolution of the arbitration must be completed within a reasonable time period following the final decision of the arbitrator(s). Any arbitration subject to this Article shall be completed within one (1) year from the
filing of notice of a request for such arbitration. The arbitration proceedings and the decision shall not be made public without the joint consent of the parties and each party shall maintain the confidentiality of such proceedings and decision
unless otherwise permitted by the other party. Any decision which requires a monetary payment shall require such payment to be payable in United States dollars, free of any tax or other deduction. The parties agree that the decision shall be the
sole, exclusive and binding remedy between them regarding any and all disputes, controversies, claims and counterclaims presented to the arbitrators. Any award may be entered in a court of competent jurisdiction for a judicial recognition of the
decision and an order of enforcement. 

  
 - 21 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 ARTICLE 15 

PRODUCT LIABILITY 
 15.1 Licensee agrees that Caltech shall have no liability to Licensee or to any purchasers or users of Licensed Products made or sold by Licensee for any claims, demands, losses, costs, or damages
suffered by Licensee, or purchasers or users of such Licensed Products, or any other party, which may result from personal injury, death, or property damage related to the manufacture, use, or sale of such Licensed Products (“Product
Claims”). Licensee agrees to defend, indemnify, and hold harmless Caltech, its trustees, officers, agents, and employees from any such Product Claims, provided that (i) Licensee is notified promptly of any Product Claims,
(ii) Licensee has the sole right to control and defend or settle any litigation within the scope of this indemnity, (iii) all indemnified parties cooperate in the defense of any Product Claims, and (iv) the Product Claims do not
involve or relate to a material breach by Caltech of its representations and warranties. 
 15.2 At such time as Licensee begins
to sell or distribute Licensed Products (other than for the purpose of obtaining regulatory approvals), Licensee shall at its sole expense, procure and maintain policies of comprehensive general liability insurance in amounts not less than [***] in
annual aggregate and naming those indemnified under Section 15.1 as additional insureds. Such comprehensive general liability insurance shall provide (i) product liability coverage and (ii) broad form contractual liability coverage
for Licensee’s indemnification under Section 15.1. In the event the aforesaid product liability coverage does not provide for occurrence liability, Licensee shall maintain such comprehensive general liability insurance for a reasonable
period of not less than five (5) years after it has ceased commercial distribution or use of any Licensed Product. 
 15.3
Licensee shall provide Caltech with written evidence of Such insurance upon request of Caltech. Licensee shall provide Caltech with notice at least fifteen (15) days prior to any cancellation, non-renewal or material change in such insurance,
to the extent Licensee receives advance notice of such matters from its insurer. If Licensee does not obtain replacement insurance providing comparable coverage within ninety (90) days following the date of such cancellation, non-renewal or
material change, Caltech shall have the right to terminate this 

  
 - 22 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
Agreement effective at the end of such ninety (90) day period without any additional waiting period; provided that if Licensee uses reasonable efforts but is unable to obtain the required
insurance at commercially reasonable rates, Caltech shall not have the right to terminate this Agreement, and Caltech instead shall cooperate with Licensee to either grant a waiver of Licensee’s obligations under this Article or assist Licensee
in identifying a carrier to provide such insurance or in developing a program for self-insurance or other alternative measures. 

ARTICLE 16 

MISCELLANEOUS 
 16.1 Licensee agrees that it shall not use the name of Caltech, or California Institute of Technology, in any advertising or publicity material, or make any form of representation or statement which would
constitute an express or implied endorsement by Caltech of any Licensed Product, and that it shall not authorize others to do so, without first having obtained written approval from Caltech, except as may be required by governmental law, rule or
regulation. 
 16.2 Licensee agrees to mark the appropriate U.S. patent number or numbers on all Licensed Products made or sold
in the United States in accordance with all applicable governmental laws, rules and regulations, and to require its Sublicensees to do the same. 
 16.3 This Agreement sets forth the complete agreement of the parties concerning the subject matter hereof. No claimed oral agreement in respect thereto shall be considered as any part hereof. No waiver of
or change in any of the terms hereof subsequent to the execution hereof claimed to have been made by any representative of either party shall have any force or effect unless in writing, signed by duly authorized representatives of the parties.

 16.4 This Agreement shall be binding upon and inure to the benefit of any successor or assignee of Caltech. This Agreement is
not assignable by Licensee without the prior written consent of Caltech, except that Licensee may assign this Agreement without the prior written consent of Caltech, to any Affiliate, or in connection with the sale or transfer of all or
substantially all the assets of Licensee relating to the Licensed Products or services utilizing the methods within the Licensed Patents. Any permitted assignee shall succeed to all of the rights and obligations of Licensee under this Agreement.

  
 - 23 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 16.5 This Agreement is subject in all respects to the laws and regulations of the United
States of America, including the Export Administration Act of 1979, as amended, and any regulations thereunder. 
 16.6 This
Agreement shall be deemed to have been entered into in California and shall be construed and enforced in accordance with California law. 
 16.7 Any notice or communication required or permitted to be given or made under this Agreement shall be addressed as follows: 

 

			
	Caltech:	  	Office of Technology Transfer
		  	California Institute of Technology
		  	1200 East California Boulevard (MC 210-85)
		  	Pasadena, CA 91125
		  	Fax No.: (626) 356-2486
		
	Licensee:	  	Fluidigm Corporation
		  	7100 Shoreline Court
		  	South San Francisco, CA 94080
		  	Attn: President
		  	Fax No: (650) 871-7195
		  	Phone: (650) 266-6000

 Either party may notify the other
in writing of a change of address or fax number, in which event any subsequent communication relative to this Agreement shall be sent to the last said notified address or number, provided, however, that the parties shall deliver all material notices
under this Agreement by registered mail or overnight delivery service. All notices and communications relating to this Agreement shall be deemed to have been given when received. 

16.8 Nothing in this Agreement will impair Licensee’s right to independently acquire, license, develop for itself, or have others
develop for it, intellectual property and technology performing similar functions as the Licensed Patents and Technology or to market and distribute products other than Licensed Products based on such other intellectual property and technology.

 16.9 NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, OR INDIRECT DAMAGES ARISING OUT
OF THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY. 

  
 - 24 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 16.10 The relationship of Licensee and Caltech established by this Agreement is that of
independent contractors, Nothing in this Agreement shall be construed to create any other relationship between Licensee and Caltech. Neither party shall have any right, power or authority to assume, create or incur any expense, liability or
obligation, express or implied, on behalf of the other. 
 16.11 Licensee agrees that a Licensed Product which embodies a
patented invention or is produced through the use thereof for sale in the United States shall be manufactured substantially in the United States to the extent required by 35 U.S.C. Section 204. 

16.12 Neither party shall lose any rights hereunder or be liable to the other party for damages or losses (except for payment
obligations) on account of failure of performance by the defaulting party if the failure is occasioned by war, strike, fire, Act of God, earthquake, flood, lockout, embargo, governmental acts or orders or restrictions, failure of suppliers, or any
other reason where failure to perform is beyond reasonable control and not caused by the negligence or intentional conduct or misconduct of the nonperforming party, and such party has exerted all reasonable efforts to avoid or remedy such force
majeure; provided, however, that in no event shall a party be required to settle any labor dispute or disturbance. 
 16.13 In
the event that any provisions of this Agreement are determined to be invalid or unenforceable by a court of competent jurisdiction, the remainder of the Agreement shall remain in full force and effect without said provision. The parties shall in
good faith negotiate a substitute clause for any provision declared invalid or unenforceable, which shall most nearly approximate the intent of the parties in entering this Agreement. 

16.14 This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. 
 16.15 The headings of the several Sections are inserted for convenience of
reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement. 

  
 - 25 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 16.16 Whenever provision is made in this Agreement for either party to secure the
consent or approval of the other, that consent or approval shall not unreasonably be withheld or delayed, and whenever in this Agreement provisions are made for one party to object to or disapprove a matter, such objection or disapproval shall not
unreasonably be exercised. 
 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed: 

 

					
	Date: 4/29/04	 	CALIFORNIA INSTITUTE OF TECHNOLOGY
		 	(Caltech)
			
		 	By:	 	 /s/ Lawrence Gilbert

		 	Name:	 	     Lawrence Gilbert
		 	Title:	 	     Senior Director
		 		 	     Office of Technology Transfer
		
	Date: April 28, 2004	 	FLUIDIGM CORPORATION
		 	(Licensee)
			
		 	By:	 	 /s/ Gajus Worthington

		 	Name:	 	     Gajus Worthington
		 	Title:	 	     President and CEO

  
 - 26 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Exhibit A 

Licensed Patents 
  

			
	Date: April 22, 2004	  	Confidential

 [***]

  
 - 27 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Exhibit A 

Licensed Patents 
 [***] 

  
 - 28 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Exhibit A 

Licensed Patents 
 [***] 

  
 - 29 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Exhibit A 

Licensed Patents 
 [***] 

  
 - 30 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Exhibit A 

Licensed Patents 
 [***] 

  
 - 31 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Exhibit A 

Licensed Patents 
 [***] 

  
 - 32 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Exhibit A 

Licensed Patents 
 [***] 

  
 - 33 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Exhibit A 

Licensed Patents 
 [***] 

  
 - 34 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Exhibit A 

Licensed Patents 
 [***] 

  
 - 35 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Exhibit A 

Licensed Patents 
 [***] 

  
 - 36 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Exhibit A 

Licensed Patents 
 [***] 

  
 - 37 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Exhibit A 

Licensed Patents 
 [***] 

  
 - 38 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Exhibit A 

Licensed Patents 
 [***] 

  
 - 39 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Exhibit A 

Licensed Patents 
 [***] 

  
 - 40 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Exhibit A 

Licensed Patents 
 [***] 

  
 - 41 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Exhibit A 

Licensed Patents 
 [***] 

  
 - 42 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Exhibit A 

Licensed Patents 
 [***] 

  
 - 43 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Exhibit A 

Licensed Patents 
 [***] 

  
 - 44 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.First Addendum to Second Amended and Restated License Agreement

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Exhibit 10.5A 

 

	
	2020.LICI.001.C
	 California Institute of

Technology

 ADDENDUM TO 
 SECOND AMENDED AND RESTATED LICENSE AGREEMENT 

THIS ADDENDUM TO SECOND AMENDED AND RESTATED LICENSE AGREEMENT (this “Addendum”) dated as of March 29, 2007 (the
“Addendum Date”), is entered into between CALIFORNIA INSTITUTE OF TECHNOLOGY (“Caltech”), having an address at 1200 East California Boulevard, Pasadena, California 91125, and FLUIDIGM CORPORATION (“Licensee”), having a
principal place of business at 7100 Shoreline Court, South San Francisco, California 94080, with respect to the following facts: 
 A. The parties entered into the Second Amended and Restated License Agreement (the “Agreement”) effective May 1, 2000, with a second restatement date as of May 1, 2004. All terms used,
but not defined herein, shall have the respective meanings set forth in the Agreement. 
 B. On the terms and conditions of
this Addendum, the parties desire to clarify and modify certain provisions to the Agreement. 
 NOW, THEREFORE, in consideration
of the foregoing premises and the mutual covenants set forth below, the parties agree as follows: 
 1. Licensed Patents and
Improvements. 
 1.1 The Agreement is amended by deleting Exhibit A to the Agreement and by replacing it with
Exhibit A to this Addendum. 
 1.2 Caltech represents that it has disclosed to Licensee all Improvements arising prior to
the Addendum Date. 
 1.3 The parties acknowledge that Exhibit A to this Addendum includes (a) all Improvements
disclosed by Caltech to Licensee prior to the Addendum Date, and elected by Licensee to be included in the scope of the license grant by Caltech to Licensee under the Agreement, and (b) all updates on all Licensed Patents as of the Addendum
Date. Caltech confirms that Licensee has taken all action on its part that is necessary for all subject matter included in Exhibit A to this Addendum to be included in the scope of the license grant by Caltech to Licensee under the Agreement.

 2. Licensee Equity Interest and Improvement Periods. 
 2.1 Notwithstanding anything to the contrary in Article 5 of the Agreement, the Improvement Periods shall be those periods from June 1, 2003 through May 31, 2004, from June 1, 2004
through May 31, 2005, from [***] 

  
 Page 1

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 2.2 Notwithstanding anything to the contrary in Article 5 of the Agreement,
(a) Licensee shall issue to Caltech [***] [***] shares of common stock of Licensee, pursuant to the terms of a reasonable and customary stock issuance agreement, and (b) the parties acknowledge that the issuance of such shares (in addition
to the shares issued by Licensee to Caltech prior to the Second Restatement Date) shall be in full satisfaction of Licensee’s obligations to issue shares or otherwise make payments to Caltech pursuant to the Agreement. 

3. Royalty Reports. 

The parties acknowledge (a) that the royalty reports received by Caltech under Section 9.2 of the Agreement prior to the
Addendum Date are presumed correct and not subject to challenge, audit or amendment, and (b) that the format of, and the methodology used by Licensee in preparing, the royalty reports under Section 9.2 of the Agreement are mutually
acceptable and in compliance with the terms and conditions of the Agreement. 
 4. Patent Costs. 

Notwithstanding anything to the contrary in Article 11 of the Agreement, Licensee shall have no obligation to reimburse Caltech for
any costs or expenses incurred by Caltech in connection with the Licensed Patents that have not been reimbursed by Licensee prior to the Addendum Date. 
 5. Further Assurances. 
 Each party shall take such further actions, and
execute such further documents and instruments, as reasonably requested by the other party to effectuate the grant of licenses and rights from Caltech to Licensee under the Agreement and otherwise to enable Licensee to enjoy the full benefit
thereof. 
 6. Miscellaneous. 
 6.1 This Addendum shall be effective for all purposes as of the Addendum Date. Except as otherwise expressly modified by this Addendum, the Agreement shall remain in full force and effect in accordance
with its terms. 
 6.2 This Addendum shall be governed by, interpreted and construed in accordance with the laws of the State of
California, without regard to conflicts of law principles. 
 6.3 This Addendum may be executed in counterparts, each of which
shall be deemed to be an original and together shall be deemed to be one and the same document. 

  
 2 

 

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 IN WITNESS WHEREOF, the parties have caused this Addendum to be duly executed and
delivered effective as of the Addendum Date. 
  

			
	 California Institute of Technology

		
	By:	 	/s/  Lawrence Gilbert
		 	(Signature)
	
	 Lawrence Gilbert

	(Printed Name)
	
	 SR DR Tech Transfer

	 (Title)

	
	Fluidigm Corporation
		
	By:	 	/s/  Gajus V. Worthington
		 	(Signature)
	
	 Gajus V. Worthington

	(Printed Name)
	
	 CEO

	(Title)

  
 3 

 

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 EXHIBIT A 
 [TO BE ATTACHED] 

  
 4 

 

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Appendix 1.7 Fluidigm Patent Family 

US Cases 
 [***]

  
 Page 1

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Appendix 1.7 Fluidigm Patent Family 

US Cases 
 [***]

  
 Page 2

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Appendix 1.7 Fluidigm Patent Family 

US Cases 
 [***]

  
 Page 3

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Appendix 1.7 Fluidigm Patent Family 

US Cases 
 [***]

  
 Page 4

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Appendix 1.7 Fluidigm Patent Family 

US Cases 
 [***]

  
 Page 5

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Appendix 1.7 Fluidigm Patent Family 

US Cases 
 [***]

  
 Page 6

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Appendix 1.7 Fluidigm Patent Family 

US Cases 
 [***]

  
 Page 7

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Appendix 1.7 Fluidigm Patent Family 

US Cases 
 [***]

  
 Page 8

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Appendix 1.7 Fluidigm Patent Family 

US Cases 
 [***]

  
 Page 9

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Appendix 1.7 Fluidigm Patent Family 

US Cases 
 [***]

  
 Page 10

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Appendix 1.7 Fluidigm Patent Family 

US Cases 
 [***]

  
 Page 11

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Appendix 1.7 Fluidigm Patent Family 

International Cases 
 [***] 

  
 Page 1

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Appendix 1.7 Fluidigm Patent Family 

International Cases 
 [***] 

  
 Page 2

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Appendix 1.7 Fluidigm Patent Family 

International Cases 
 [***] 

  
 Page 3

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Appendix 1.7 Fluidigm Patent Family 

International Cases 
 [***] 

  
 Page 4

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Appendix 1.7 Fluidigm Patent Family 

International Cases 
 [***] 

  
 Page 5

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Appendix 1.7 Fluidigm Patent Family 

International Cases 
 [***] 

  
 Page 6

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Appendix 1.7 Fluidigm Patent Family 

International Cases 
 [***] 

  
 Page 7

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Appendix 1.7 Fluidigm Patent Family 

International Cases 
 [***] 

  
 Page 8

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Appendix 1.7 Fluidigm Patent Family 

International Cases 
 [***] 

  
 Page 9

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Appendix 1.7 Fluidigm Patent Family 

International Cases 
 [***] 

  
 Page 10

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}]]